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TBC1D1(tre-2/USP6,BUB2,cdc16domainfamilymember1)is
aRab-GAP(GTPase-activatingprotein)thatishighlyexpressedin
skeletal muscle, but little is known about TBC1D1 regulation and
function.WestudiedTBC1D1phosphorylationonthreepredicted
AMPK (AMP-activated protein kinase) phosphorylation sites
(Ser
231,S e r
660 and Ser
700) and one predicted Akt phosphorylation
site (Thr
590) in control mice, AMPKα2 inactive transgenic mice
(AMPKα2i TG) and Akt2-knockout mice (Akt2 KO). Muscle
contraction signiﬁcantly increased TBC1D1 phosphorylation on
Ser
231 and Ser
660, tended to increase Ser
700 phosphorylation, but
had no effect on Thr
590. AICAR (5-aminoimidazole-4-carboxy-
amide ribonucleoside) also increased phosphorylation on Ser
231,
Ser
660 and Ser
700, but not Thr
590, whereas insulin only increased
Thr
590 phosphorylation. Basal and contraction-stimulated
TBC1D1 Ser
231,S e r
660 and Ser
700 phosphorylation were greatly
reduced in AMPKα2i TG mice, although contraction still elicited
a small increase in phosphorylation. Akt2 KO mice had blunted
insulin-stimulated TBC1D1 Thr
590 phosphorylation. Contraction-
stimulated TBC1D1 Ser
231 and Ser
660 phosphorylation were
normal in high-fat-fed mice. Glucose uptake in vivo was signiﬁ-
cantly decreased in tibialis anterior muscles overexpressing
TBC1D1mutatedonfourpredictedAMPKphosphorylationsites.
In conclusion, contraction causes site-speciﬁc phosphorylation
of TBC1D1 in skeletal muscle, and TBC1D1 phosphorylation
on AMPK sites regulates contraction-stimulated glucose uptake.
AMPK and Akt regulate TBC1D1 phosphorylation, but there
must be additional upstream kinases that mediate TBC1D1
phosphorylation in skeletal muscle.
Key words: Akt, AMP-activated protein kinase (AMPK), con-
traction, glucose transport, skeletal muscle, TBC1D1.
INTRODUCTION
Skeletal muscle is a major target tissue for insulin-stimulated
glucose disposal [1,2], and insulin resistance in this tissue is
considered a key factor in the development of Type 2 diabetes.
Insulin-stimulatedmuscleglucosetransportisimpairedinpatients
with Type 2 diabetes [3,4], whereas exercise-stimulated glucose
transport is normal, or near normal [5–7]. Both exercise and
insulin increase glucose transport through the translocation
of GLUT4 (glucose transporter 4)-containing vesicles from
intracellular depots to the transverse tubules and sarcolemma [8–
13]. Although it is well-established that the proximal signalling
mechanisms that lead to exercise- and insulin-stimulated GLUT4
translocation are distinct, there is now extensive evidence that
there is a convergence of exercise and insulin signalling at
TBC1D1 (tre-2/USP6, BUB2, cdc16 domain family member
1) and AS160 (Akt substrate of 160 kDa; also known as
TBC1D4). TBC1D1 and AS160 are highly homologous Rab-
GAPs (GTPase-activating proteins). There has been considerably
more investigation of AS160, and this protein is postulated to
function by promoting hydrolysis of GTP to GDP on GLUT4-
containing vesicles. In the GDP-bound form, the GLUT4-con-
taining vesicles are bound to speciﬁc Rab proteins, inhibiting
GLUT4 translocation to the cell surface [14]. Site-speciﬁc
phosphorylation of AS160 is thought to modulate Rab-GAP
activity, allowing release of the transporters to the membranes.
While AS160 has been studied in both skeletal muscle (e.g.
[15,16]) and adipocytes [17], much less is known about the
regulation and function of TBC1D1 [14,18,19]. TBC1D1 is
similar to AS160 in terms of size and structure [20]. However,
thetissuedistributionofthetwoproteinsisconsiderablydifferent,
withTBC1D1havinglittleifanyexpressioninadipocytes,andthe
highest level of expression in skeletal muscle [21,22]. We found
that contraction, insulin and the AMPK (AMP-activated protein
kinase) activator AICAR (5-aminoimidazole-4-carboxyamide
ribonucleoside) increase TBC1D1 phosphorylation on PAS
(phospho-Akt substrate) motifs in mouse skeletal muscle,
demonstratingthatTBC1D1isanadditionalpointofconvergence
for insulin and contraction signalling [21]. More recently, others
have also shown TBC1D1 PAS phosphorylation in response to
exercise and insulin in rat and mouse skeletal muscle [23,24].
In addition to Akt, there is strong evidence that there are other
kinases that can phosphorylate TBC1D1, most notably AMPK.
For example, we found that phosphorylation of skeletal muscle
TBC1D1 with recombinant AMPK in vitro, but not recombinant
Akt, induced an electrophoretic-mobility shift. Consistent with
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this hypothesis, we identiﬁed several novel phosphorylation sites
on endogenous TBC1D1 from skeletal muscle using MS [21].
Several of these sites, including Ser
231,T h r
499,S e r
660 and Ser
700,
areconsensusornear-consensussitesforAMPKphosphorylation
motifs{ [Xβ]XX(S/T)XXX ; =methionine,valine,leucine,
isoleucine or phenylalanine, β = arginine, lysine or histidine,
and X = any amino acid} [25] and/or are suggested to be
phosphorylatedbytheAMPKactivatorAICAR,basedonrelative
peak ion intensities, a semi-quantitative method of analysis [21].
One purpose of the present study was to determine the effects
of contraction, insulin and the AMPK activator AICAR on
phosphorylation of these TBC1D1 sites.
ThereisgrowingevidencethatTBC1D1isinvolvedintheregu-
lation of glucose transport. In 3T3-L1 adipocytes, mutation
of multiple Akt sites impairs insulin-stimulated GLUT4
translocation [26]. In skeletal muscle, we found that expression
of the obesity-associated R125W mutant signiﬁcantly decreased
insulin-stimulated glucose transport in the absence of changes
in TBC1D1 PAS phosphorylation [27]. Surprisingly, expression
ofTBC1D1mutatedtoalanineonfourconservedphosphorylation
sites had no effect on insulin-stimulated glucose transport, but
impaired contraction-stimulated glucose uptake [27]. Whether
mutation of the multiple putative AMPK sites on TBC1D1
regulates glucose uptake in skeletal muscle has not been investi-
gated, and this is another major goal of the present study. Our
ﬁndings from the present study indicate that muscle contraction
is a signiﬁcant regulator of TBC1D1 phosphorylation in skeletal
muscle, and that simultaneous mutation of multiple sites impairs
contraction-stimulated glucose uptake.
EXPERIMENTAL
Animals
Protocols for animal use were reviewed and approved by the
Institutional Animal Care and Use Committee of the Joslin
Diabetes Center and were in accordance with National Institutes
of Health guidelines. Female ICR (imprinting control region)
mice 8–9 weeks old (25–30 g) were purchased from Charles
RiverLaboratoriesorTaconic.Femalemuscle-speciﬁcAMPKα2i
TG (α2-inactive AMPK transgenic) mice and WT (wild-type)
littermates (FVB background; aged 9 weeks) were generated as
describedpreviously[28].FemaleAkt2KO(Akt2knockout)mice
and WT littermates (C57BL/6N background; aged 9 weeks) were
kindly provided by Dr Morris Birnbaum [29]. All mice
were housed in a 12 h:12 h light/dark cycle. The ICR, AMPKα2i
TG and Akt KO mice were fed standard laboratory chow and
water ad libitum. For the high-fat diet studies, 6-week-old
C57BL/6NHsd male mice were fed on a high-fat diet (60%
kcal of fat) from Harlan Labs for 9 weeks (TD.06414). Mice
were restricted from food overnight (20:00 to 09:00 h) prior to
experiments.
Plasmid cDNA constructs
The plasmid encoding mouse WT TBC1D1 (long form) was
generated in our laboratory [27]. Five mutant TBC1D1 constructs
were generated using the QuikChange® II XL mutagenesis kit
(Stratagene). This included WT TBC1D1, TBC1D1 mutated on
four predicted AMPK phosphorylation sites (Ser
231,T h r
499,S e r
660
and Ser
700) to alanine (4A mutant) and TBC1D1 mutated on
each site individually. Mutations of the TBC1D1 constructs were
conﬁrmed for accuracy by utilizing the high-throughput DNA
sequencing service at Brigham and Women’s Hospital (Boston,
MA, U.S.A.). Plasmid DNA was ampliﬁed in Escherichia coli
TOP10 cells (Invitrogen), extracted using an endotoxin-free
Plasmid Mega Kit (Qiagen) and suspended in saline at 4 μg/μl.
In vivo gene transfer in mouse skeletal muscle and in vivo glucose
uptake
Animals were anaesthetized with an intraperitoneal injection of
pentobarbital sodium (90–100 mg/kg of body weight). Plasmid
DNA (100 μg; empty pCAGGS vector, WT TBC1D1 or mutant
TBC1D1 constructs) were directly injected into mouse tibialis
anterior muscles followed by electroporation according to our
modiﬁed protocol [30], originally described by Aihara and
Miyazaki [31]. At 7 days after DNA injection, the mice were
used to measure contraction-mediated glucose uptake or to test
phospho-speciﬁc antibodies (see below). Rates of glucose uptake
into skeletal muscle were assessed as described previously [32].
In situ muscle contraction
Micewereanaesthetizedwithanintraperitonealadministrationof
pentobarbital sodium (90–100 mg/kg of body weight). Peroneal
nerves from both legs were surgically exposed. One leg served
as a sham-operated control, while the other leg was subjected
to electrical stimulation using a Grass S88 pulse generator for
15 min (train rate, 1/s; train duration, 500 ms; pulse rate, 100 Hz;
duration, 0.1 ms at 1–8 V). Voltage and electrode position were
manually adjusted so that muscles were contracted with a full
range of motion.
In vitro muscle incubation
Mice were anaesthetized as described above and EDL (extensor
digitorum longus) muscles were dissected. EDL muscles were
pre-incubated in Krebs–Ringer bicarbonate buffer with 2 mmol/l
pyruvate for 20 min as described previously [33]. After the pre-
incubation period, muscles were incubated in the absence or
presence of 2 mmol/l AICAR for 40 min and rapidly frozen in
liquid nitrogen.
In vivo insulin administration
Mice were anaesthetized as described above followed by
intraperitoneal injection of saline (0.9% NaCl) or a maximal
dose of insulin (1 unit). Then, 10 min later, mice were killed by
cervical dislocation, and tibialis anterior muscles were rapidly
removed and frozen in liquid nitrogen.
Tissue processing and immunoblotting
Frozen muscles were pulverized and homogenized with a
Polytron (Brinkman Instruments) in ice-cold buffer as described
in [21]. Lysates (20 μg of protein) were separated by SDS/
PAGE and transferred on to nitrocellulose membrane
(PerkinElmer Life Sciences) for Western blotting. A horseradish-
peroxidase-conjugated anti-rabbit antibody (Amersham Bios-
ciences) was used to bind and detect all of the primary
antibodies. Antibody-bound proteins were detected by enhanced
chemiluminescence reagent (PerkinElmer Life Sciences) and
visualized on the FluorChem® imaging system (Alpha Innotech).
The FluorChem®-detected protein bands were quantiﬁed by
densitometry (AlphaEaseFC software 4.0; Alpha Innotech).
TBC1D1 phosphorylation was measured using immunopuriﬁed
phospho-speciﬁc antibodies against Ser
231,T h r
590,S e r
660 and
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Figure 1 TBC1D1 Ser231 phosphorylation is increased by contraction and AICAR
(A) Contraction (Ctxn) increased TBC1D1 Ser231 phosphorylation in tibialis anterior muscles from ICR mice. Mice were anaesthetized and contraction was generated by electrical stimulation of
the peroneal nerve for 15min, while the contra-lateral side served as a sham-operated control. (B) AICAR increased TBC1D1 Ser231 phosphorylation. EDL muscles were isolated from ICR mice
and incubated with 2 mM AICAR or vehicle for 40min. (C) Phosphorylation of TBC1D1 Ser231 was reduced in AMPKα2i TG mice. AMPKα2i TG mice and WT littermates underwent contraction
as described in (A). (D) Basal and contraction-stimulated TBC1D1 Ser231 was preserved in Akt2 KO mice. Akt2 KO mice and WT littermates underwent contraction as described in (A). Data are
means+ −S.E.M.; n = 5–7/group. *P < 0.05 compared with control; †P < 0.05 compared with corresponding WT. AU, arbitrary units.
Ser
700, and TBC1D1 protein expression was detected using
immunopuriﬁed anti-TBC1D1 antibody. TBC1D1 antibodies
were developed in collaboration with Cell Signaling Technology.
Speciﬁcity of the anti-phospho-TBC1D1 Ser
231,T h r
590,S e r
660
and Ser
700 antibodies were validated using tibialis anterior
muscles that had been individually transfected with TBC1D1
mutated at each phosphorylation site to alanine, compared with
WT TBC1D1-overexpressing muscles and empty-vector-injected
control muscles (Supplementary Figure S1A–S1D at http://
www.BiochemJ.org/bj/431/bj4310311add.htm).
Statistical analysis
Data are presented as means+ −S.E.M. Statistical analyses were
performedusinganunpairedStudent’st testortwo-wayANOVA.
When ANOVA revealed signiﬁcant differences, a Student–
Newman–Keuls post-hoc test was performed. P values less than
0.05 were considered statistically signiﬁcant.
RESULTS
TBC1D1 phospho-antibodies
Our previous study identiﬁed multiple phosphorylation sites on
endogenous TBC1D1 from skeletal muscle [21]. On the basis
of semi-quantitative analysis of our MS results [21], scan-site
analysis of the sequences [34] and other published data [20,26],
we predicted that Ser
231,S e r
660 and Ser
700 would be strongly
regulated by AMPK, Ser
499 weakly regulated by AMPK and
Thr
590 regulated by Akt. To investigate site-speciﬁc regulation
of TBC1D1 phosphorylation, we set out to generate antibodies
against these ﬁve TBC1D1 residues: Ser
231,S e r
499,T h r
590,S e r
660
and Ser
700 (Supplementary Figure S1). Of these, we were
not successful in generating the Ser
499 antibody. Therefore for
subsequentexperimentswefocusedonTBC1D1phosphorylation
on Ser
231,T h r
590,S e r
660 and Ser
700.
Muscle contraction and AICAR increase TBC1D1 Ser231
phosphorylation
Since Ser
231 of TBC1D1 is a consensus match for the AMPK
phosphorylation motif, we hypothesized that stimuli that
increase AMPK activity would increase TBC1D1 Ser
231
phosphorylation in skeletal muscle. Using an antibody speciﬁc
for TBC1D1 phosphorylation at Ser
231, we investigated the site-
speciﬁc regulation of TBC1D1 phosphorylation in response
to muscle contraction, AICAR and insulin. Contraction of
tibialis anterior muscle in situ for 15 min increased Ser
231
phosphorylation by approx. 2-fold compared with sham-treated
muscles (Figure 1A). In addition, incubation of isolated
EDL muscles with AICAR for 40 min increased TBC1D1 Ser
231
phosphorylation by nearly 4-fold compared with basal control
muscles (Figure 1B). To determine whether AMPKα2 regulates
contraction-induced increases in Ser
231 phosphorylation, we
studiedWTandAMPKα2iTGmice[28].Underbasalconditions,
Ser
231 phosphorylation was nearly abolished in tibialis anterior
muscles from AMPKα2i TG mice compared with WT controls
(Figure 1C). In situ contraction increased Ser
231 phosphorylation
in the WT mice, an effect that was markedly impaired in
the AMPKα2i TG mice. However, the lack of AMPKα2
activity did not fully inhibit TBC1D1 Ser
231 phosphorylation.
These data demonstrate that AMPKα2 regulates TBC1D1 Ser
231
phosphorylation under basal conditions, and also contributes
to contraction-mediated Ser
231 phosphorylation. However, there
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Figure 2 TBC1D1 Ser660 phosphorylation is regulated by contraction and AICAR
Experimental details are as described in the legend to Figure 1. (A) Contraction (Ctxn) in situ for 15min increased TBC1D1 Ser660 phosphorylation in tibialis anterior muscles from ICR mice.
(B)AICARincreasedTBC1D1Ser660 phosphorylation.(C)PhosphorylationofTBC1D1Ser660 wasreducedinAMPKα2iTGmice.(D)Basalandcontraction-stimulatedTBC1D1Ser660 waspreserved
in Akt2 KO mice. Data are means+ −S.E.M.; n = 5–7/group. *P < 0.05 compared with control; †P < 0.05 compared with corresponding WT. AU, arbitrary units.
must be one or more additional upstream kinases that mediate the
effects of muscle contraction on TBC1D1 Ser
231 phosphorylation.
MusclecontractionincreasesAkt2phosphorylationandactivity
in skeletal muscle [33]. To determine whether Akt2 regulates
contraction-stimulated TBC1D1 Ser
231 phosphorylation, WT and
Akt2 KO mice were studied in the basal state and after in situ
muscle contraction. In contrast with experiments using the
AMPKα2i mice, knockout of Akt2 had no effect on
basal or contraction-stimulated TBC1D1 Ser
231 phosphorylation
(Figure 1D).
To study the effects of insulin on TBC1D1 Ser
231 phosphoryl-
ation, anaesthetized mice were injected with saline or a
maximal dose of insulin, and tibialis anterior muscles were
dissected 10 min later. Insulin had no effect on Ser
231
phosphorylation (Supplementary Figure S2A at http://www.
BiochemJ.org/bj/431/bj4310311add.htm). Consistent with this
ﬁnding, there was no change in basal or insulin-stimulated Ser
231
phosphorylation in Akt2 KO mice (Supplementary Figure S2B).
These data demonstrate that insulin and Akt2 do not regulate
TBC1D1 Ser
231 phosphorylation.
Muscle contraction and AICAR increase TBC1D1 Ser660
phosphorylation
TBC1D1 Ser
660 on endogenous TBC1D1 was identiﬁed through
MS [21], and this phosphorylation site is a consensus match
for the AMPK phosphorylation motif, except for the lack of
one basic residue at either the −3o r−4 position. Contraction
in situ signiﬁcantly increased Ser
660 phosphorylation in tibialis
anterior muscles by approx. 1.5-fold compared with sham-
treated muscles (Figure 2A). Incubation of EDL muscles with
AICARincreasedSer
660 phosphorylationby2.5-fold(Figure2B).
To determine whether AMPKα2 regulates contraction-induced
increases in Ser
660 phosphorylation, we studied WT and
AMPKα2i TG mice. Similar to Ser
231, TBC1D1 Ser
660
phosphorylation in the basal state was severely blunted in tibialis
anterior muscles from the AMPKα2i TG mice (Figure 2C).
In situ contraction increased Ser
660 phosphorylation in the WT
mice, and in the AMPKα2i TG mice there was a tendency to
increase TBC1D1 Ser
660 phosphorylation, although this did not
reach statistical signiﬁcance (Figure 2C). Contraction similarly
increased Ser
660 phosphorylation in WT and Akt2 KO mice
(Figure 2D). Maximal insulin stimulation in vivo did not increase
TBC1D1 Ser
660 phosphorylation (Supplementary Figure S2C),
and Akt2 KO mice had normal basal levels of TBC1D1 Ser
660
phosphorylation (Figure 2D and Supplementary Figure S2D).
Taken together, these data suggest that Ser
231 and Ser
660 share
similar regulatory mechanisms. Both sites exhibit signiﬁcant
increases in phosphorylation in response to contraction and
AICAR, and both sites are regulated by AMPKα2, but not by
insulin or Akt2.
TBC1D1 Ser700 phosphorylation
Similar to Ser
231,t h eS e r
700 phosphorylation site on TBC1D1 is a
full consensus match for the AMPK phosphorylation motif [21].
However, in contrast with Ser
231 and Ser
660, muscle contraction in
situ only tended to increase Ser
700 phosphorylation (Figure 3A).
AICAR treatment of EDL muscles in vitro signiﬁcantly
increased Ser
700 phosphorylation by 2-fold (Figure 3B). In the
AMPKα2i TG mice, basal levels of Ser
700 phosphorylation
were signiﬁcantly decreased compared with WT littermates
(Figure 3C). In these experiments, contraction also tended to
increase Ser
700 phosphorylation in WT mice, and signiﬁcantly
increased phosphorylation in the AMPKα2i TG mice, although
to a much lower overall level of phosphorylation compared with
t h eW Tm i c e( F i g u r e3 C ) .A k t 2K Om i c eh a dn o r m a ll e v e l s
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Figure 3 TBC1D1 Ser700 phosphorylation is increased by AICAR, but only responds minimally to contraction
Experimental details are as described in the legend to Figure 1. (A) Contraction (Ctxn) in situ for 15min tended to increase TBC1D1 Ser700 phosphorylation in tibialis anterior muscles from ICR
mice. (B) AICAR increased TBC1D1 Ser700 phosphorylation. (C) Phosphorylation of TBC1D1 Ser700 was reduced in AMPKα2i TG mice. (D) TBC1D1 Ser700 phosphorylation was preserved in Akt2
KO mice. Data are means+ −S.E.M.; n = 5–7/group. *P < 0.05 compared with control; †P < 0.05 compared with corresponding WT. AU, arbitrary units.
of TBC1D1 Ser
700 phosphorylation under basal and contraction
conditions (Figure 3D).
Insulin stimulation did not signiﬁcantly alter Ser
700
phosphorylation (Supplementary Figure S2E), and there was no
change in basal or insulin-stimulated Ser
700 phosphorylation in
Akt2 KO mice (Supplementary Figure S2F). Thus, similar to
Ser
231 and Ser
660,A M P K α2, but not Akt2, controls basal levels of
TBC1D1Ser
700 phosphorylation.TBC1D1Ser
700 phosphorylation
tends to increase with muscle contraction; however, that increase
is much lower compared with increases in phosphorylation at
Ser
231 and Ser
660.
TBC1D1 Thr590 phosphorylation is regulated by insulin and Akt2
Thr
590 is a predicted Akt motif that is phosphorylated in response
to insulin in 3T3-L1 adipocytes and corresponds to Thr
649 in
AS160 [20,21]. Contraction and AICAR did not increase Thr
590
phosphorylation in muscle (Supplementary Figures S3A and S3B
at http://www.BiochemJ.org/bj/431/bj4310311add.htm). In spite
of the lack of Thr
590 phosphorylation with these two AMPK-
activating stimuli, in the AMPKα2i TG mice, basal levels of
Thr
590 phosphorylation were signiﬁcantly decreased compared
withWTlittermates(Figure4A).Asexpected,insulinstimulation
in vivo signiﬁcantly increased TBC1D1 Thr
590 phosphorylation
in muscle (Figure 4C). This effect was mediated by Akt2, as the
insulin-stimulatedincreaseinTBC1D1wasabolishedintheAkt2
KO mice (Figure 4D). However, there was no change in basal
levels of Thr
590 phosphorylation in the Akt2 KO mice (Figures 4B
and 4D). Taken together, these data suggest that, while Akt2
mediates insulin-stimulated TBC1D1 Thr
590 phosphorylation,
AMPKα2 activity is important for maintaining levels of Thr
590
phosphorylation in the basal state.
Effects of a high-fat diet on TBC1D1 phosphorylation
To determine whether an animal model of insulin resistance alters
TBC1D1phosphorylationwithmusclecontraction,micewerefed
on a high-fat diet (60% kcal of fat) for 9 weeks. After 9 weeks
of high-fat feeding, mice had signiﬁcantly higher body weights,
fasting blood glucose concentrations and fasting insulin concen-
trations compared with chow-fed mice (Supplementary Table S1
at http://www.BiochemJ.org/bj/431/bj4310311add.htm). High-
fat feeding did not change the expression of total TBC1D1
in the tibialis anterior muscles (Figure 5A). High-fat feeding
also had no effect on basal levels of TBC1D1 Ser
231 and Ser
660
phosphorylation (Figures 5B and 5C). Contraction in situ for
15 min signiﬁcantly increased Ser
231 and Ser
660 phosphorylation,
and there was no effect of the high-fat feeding (Figures 5B and
5C). There was also no effect of high-fat feeding on TBC1D1
Ser
700 andThr
590 phosphorylationinthe basalstate orwith muscle
contraction (Figures 5D and 5E).
Mutation of TBC1D1 on AMPK consensus sequences decreases
contraction-stimulated glucose uptake
To determine whether TBC1D1 phosphorylation at AMPK
consensus sites regulates glucose uptake in contracted muscle,
we mutated four phosphorylation sites on TBC1D1 (4A mutant)
(Ser
231,T h r
499,S e r
660 and Ser
700) and expressed this mutant
TBC1D1 and WT TBC1D1 in tibialis anterior muscle. As shown
above, Ser
231,S e r
660 and Ser
700 are phosphorylated by AMPK,
and our previous work predicts that Thr
499 is an AMPK site
[21]. Compared with endogenous levels of TBC1D1 in empty
vector-injected control muscles, there was a 5-fold increase in
WT and 4A mutant TBC1D1 expression in the tibialis anterior
muscles (Figure 6A). Muscle contraction increased glucose
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Figure 4 TBC1D1 Thr590 phosphorylation is regulated by insulin, but not contraction or AICAR
(A) Phosphorylation of TBC1D1 Ser590 was signiﬁcantly reduced in AMPKα2i TG mice at rest. Contraction (Ctxn) in situ for 15min increased phosphorylation in AMPKα2i TG mice, but the
increase after contraction in WT mice was not statistically signiﬁcant. (B) The response to contraction was not affected in Akt2 KO mice. (C) Maximal insulin injection increased TBC1D1 Ser590
phosphorylation in ICR mice. Mice were fasted and injected intraperitoneally with maximal insulin or saline, and tibialis anterior muscles were dissected 10min later. (D) Maximal insulin injection
increased TBC1D1 Ser590 phosphorylation in WT mice, and the effect was ablated in Akt2 KO mice. Treatment was the same as described in (C). Data are means+ −S.E.M.; n = 5–7/group.
*P < 0.05 compared with control; †P < 0.05 compared with corresponding WT. AU, arbitrary units.
uptake by 5-fold in control muscles, and overexpression of
WT TBC1D1 did not alter contraction-mediated glucose uptake
(Figure 6B). However, contraction-stimulated glucose uptake
was signiﬁcantly decreased in muscles overexpressing the 4A
TBC1D1 mutant. In contrast with the effects of simultaneous
mutation of the four predicted AMPK sites, overexpression
of the individual TBC1D1 mutants had no effect on basal or
contraction-stimulated glucose uptake (Supplementary Figure S4
at http://www.BiochemJ.org/bj/431/bj4310311add.htm). These
ﬁndings suggest that phosphorylation of TBC1D1 at multiple
AMPK consensus sites is necessary for normal contraction-
stimulated glucose uptake in skeletal muscle.
DISCUSSION
Glucose disposal into skeletal muscle is critical for the main-
tenance of glucose homoeostasis, and insulin- and exercise-
stimulated glucose uptake into muscle are the most physiol-
ogically relevant stimuli in humans and rodents. It is now
well-established that the proximal intracellular signalling
molecules regulating exercise-stimulated glucose uptake in
skeletal muscle are distinct from that of insulin [14], but the
signalling systems converge at AS160 and TBC1D1. AS160
phosphorylation has been investigated in contracting skeletal
muscle (e.g. [15,35,36]), and we have studied the role of AS160
in glucose uptake [32,37]. However, much less is known about
the regulation and function of TBC1D1.
While AS160 is ubiquitously expressed, the expression of
TBC1D1 is highest in skeletal muscle, with very limited
expression (e.g. adipocytes) or no expression (e.g. heart) in other
tissues throughout the body [21]. This suggests that TBC1D1 has
a more specialized function, unique to the properties of skeletal
muscle. Therefore we hypothesized that TBC1D1 may have a
primary function of mediating signalling inputs derived from
muscle contraction. The results of the present study show that
muscle contraction increases the phosphorylation of TBC1D1
on multiple sites, including Ser
231,S e r
660, and to a lesser extent
Ser
700. On the basis of our initial MS work [21] and the AMPK
consensus sequence [25], these three amino acid residues are
predicted AMPK phosphorylation sites, which is consistent with
our ﬁnding that AICAR strongly increased phosphorylation of
all three sites. The greater AICAR response compared with the
effects of muscle contraction is likely to be due to the more potent
effectsofAICARtoincreaseAMPKphosphorylationandactivity
[15,38]. The lower degree of contraction- and AICAR-stimulated
Ser
700 phosphorylation compared with Ser
231 and Ser
660 could be
due to a number of factors, including a higher level of Ser
700
phosphorylation in the basal state. The ﬁnding that insulin did
not increase phosphorylation of Ser
231,S e r
660 and Ser
700 is also
consistent with AMPK regulation, since insulin does not increase
AMPK activity [38]. Thus while both insulin and contraction
signalling converge at TBC1D1, the two stimuli exert a distinct
pattern of phosphorylation on this Rab-GAP.
An important question is to determine the upstream kinase
or kinases that mediate the effects of muscle contraction on
TBC1D1 phosphorylation. Muscle contraction and exercise
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Figure 5 High-fat diet does not affect contraction-stimulated TBC1D1 phosphorylation
(A)TBC1D1expressionwasnotalteredintibialisanteriormusclesofmicefedonahigh-fatdiet(60%kcaloffat)for9weeks.(B–F)High-fatfeedinghadnoeffectonbasalorcontraction-stimulated
levels of (B) TBC1D1 Ser231 phosphorylation, (C) TBC1D1 Ser660 phosphorylation, (D) TBC1D1 Ser700 phosphorylation, (E) TBC1D1 Thr590 or (F) PAS phosphorylation at 150–160kDa. Data are
means+ −S.E.M.; n = 6/group. *P < 0.05 compared with control. AU, arbitrary units; Ctxn, contraction.
activate numerous signalling responses in skeletal muscle
including AMPK [39]. The basal level of phosphorylation of
TBC1D1 on Ser
231,S e r
660 and Ser
700 was signiﬁcantly reduced
in muscles from AMPKα2i TG mice, demonstrating that even
low levels of AMPK activity, which are found in the unstimu-
lated or resting condition, are necessary to maintain TBC1D1
phosphorylation in the muscle. Contraction-stimulated
TBC1D1 phosphorylation was signiﬁcantly reduced in the
AMPKα2i TG mice, but, interestingly, contraction still resulted
in a small increase in phosphorylation of all three sites. Therefore
TBC1D1 phosphorylation on Ser
231,S e r
660 and Ser
700 is not
solely dependent on AMPK, implicating regulation by additional
upstream kinases. One possibility is Akt2, since under some
conditions muscle contraction increases Akt phosphorylation
and activity [15,33,35]. However, given that we found both basal
and contraction-stimulated TBC1D1 phosphorylation of Ser
231,
Ser
660 and Ser
700 to be normal in the muscle of the Akt2 KO mice,
it is unlikely that Akt2 plays a regulatory role. In addition to Akt,
exercise and muscle contraction increase the activity of multiple
kinases in skeletal muscle including ERK1/2 (extracellular-
signal-regulated kinase 1/2), JNK (c-Jun N-terminal kinase), p38
MAPK (mitogen-activated protein kinase), the AMPK-related
kinase SNARK (sucrose-non-fermenting protein kinase) and
CaMKII (Ca
2+/calmodulin-dependent protein kinase II) [39,40].
Given that AMPKα2-inactive TG mice and AMPKα2K O
mice have normal or near normal increases in contraction-
stimulated glucose uptake [28,41,42], both in vitro and in vivo,
the regulation of TBC1D1 phosphorylation by these other
kinases may be critical in glucose uptake regulation.
Interestingly, compound C has recently been reported to decrease
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Figure 6 Overexpression of the TBC1D1 4A mutant impairs contraction-stimulated glucose uptake
To determine whether TBC1D1 phosphorylation at AMPK consensus sites regulates glucose uptake in contracted muscle, four phosphorylation sites on TBC1D1 (Ser231, Thr499,S e r 660 and Ser700)
were mutated to alanine (4A) and this mutant and WT TBC1D1 were expressed in tibialis anterior muscles. (A) Representative Western blot of total TBC1D1 showing overexpression 7days after
plasmidDNAinjections.(B)Contraction-stimulatedglucoseuptakewasnotaffectedbyoverexpressionofWTTBC1D1,whereasexpressionoftheTBC1D14Amutantimpairedcontraction-stimulated
glucose uptake by 42%. Data are means+ −S.E.M.; n = 8–15/group. *P < 0.05 compared with contraction-stimulated empty vector (EV) controls. Ctxn, contraction.
contraction-stimulated TBC1D1 PAS phosphorylation and
glucose uptake in rat epitrochlearis muscle [43]. Whether this
decrease in PAS phosphorylation was associated with decreases
in AMPK activity or muscle contractility was not determined,
making it difﬁcult to determine the exact mechanism of the
inhibitor compound. Nevertheless, this work is another example
whereTBC1D1phosphorylationstatusisassociatedwith glucose
uptake. In future studies it will be important to determine whether
thesecontraction-stimulatedproteinsorotherproteinscanbehave
as TBC1D1 kinases, and whether these kinases could function as
redundant signals regulating glucose transport in the absence of
AMPK.
Consistent with the fact that TBC1D1 Thr
590 is a full Akt con-
sensus motif, we found that insulin increased TBC1D1 Thr
590
phosphorylation in skeletal muscle, and this effect of insulin was
dependenton Akt2. TBC1D1 Thr
590 hasalso been suggestedto be
a partial AMPK consensus motif [26], but, in our present study,
contraction and AICAR had no effect on Thr
590 phosphorylation.
In contrast, it has been reported that contraction increased
TBC1D1 Thr
590 phosphorylation, and that this increase was
abolished in AMPKα2 kinase-dead mice [24]. The reason for
this discrepancy is not obvious, but could be due to differences in
stimulation protocols or differences in antibody speciﬁcity. The
function of Thr
590 is not known, but there are several lines of
evidence to suggest that it may not function in the regulation
of glucose uptake in adult skeletal muscle. While it is established
that insulin increases TBC1D1 Thr
590 phosphorylation in muscle
(the present study and [24]), phosphorylation of this site has
no effect on 14-3-3 binding, and this binding is thought to be
essential for the regulation of glucose uptake [24]. Furthermore,
we found that mutation of Thr
590 to alanine, along with three
other conserved TBC1D1 phosphorylation sites, had no effect on
insulin-stimulated glucose uptake in muscle [27]. In addition, in
thepresentstudythecontractionprotocolusedstimulatedglucose
uptake without concomitant phosphorylation of Thr
590, providing
evidence that this site is also not essential for contraction-
stimulated glucose uptake. It is also interesting that TBC1D1
Thr
590 phosphorylation does fully correlate with contraction- and
AICAR-stimulated PAS phosphorylation. It is possible that a site
other than TBC1D1 Thr
590,s u c ha sS e r
501, which is an established
Aktsite[26],maybemorecriticalinregulatinginsulin-stimulated
glucose uptake in skeletal muscle.
Our previous study has shown that mutation of four highly
conserved TBC1D1 phosphorylation sites that represent both Akt
or AMPK consensus motifs (Ser
231,T h r
499,T h r
590 and Ser
621)
impaired contraction-stimulated glucose uptake, but had no effect
on insulin-stimulated glucose uptake. However, the decrease
in contraction-stimulated glucose uptake was 22%, suggesting
that other sites on TBC1D1 may also function in contraction-
regulated glucose uptake. In the present study we mutated the
phosphorylation sites that we had shown were responsive to
contraction (Ser
231,S e r
660 and Ser
700), as well as Thr
499,a n
AMPK consensus site [21]. In mutating all four of these sites
simultaneously,wefoundanevengreaterdecreaseincontraction-
stimulated glucose transport (42%) compared with our previous
study (22%) [27]. Interestingly, we found that expression of
single point mutants had no effect on contraction-stimulated
glucose uptake in skeletal muscle. Taken together, these data
raise the possibility that multiple phosphorylation sites may
work co-operatively to control TBC1D1 Rab-GAP activity and,
subsequently, glucose uptake.
In conclusion, signals emanating from muscle contraction
and insulin both phosphorylate TBC1D1, but the pattern of
phosphorylationisdistinctforthetwostimuli.AMPKα2andAkt2
phosphorylate TBC1D1, but there must be additional upstream
kinasesthatphosphorylateTBC1D1inskeletalmuscle.Wefound
that contraction-stimulated TBC1D1 phosphorylation was not
affected by diet-induced insulin resistance, consistent with most
of the literature showing that high-fat-fed animals have normal
increases in exercise- or contraction-stimulated glucose uptake
[44,45]. Our data establish TBC1D1 as an important regulator of
contraction-stimulated glucose uptake in skeletal muscle. Given
that TBC1D1 expression is highly speciﬁc to skeletal muscle,
pharmacological inhibition of TBC1D1 Rab-GAP activity may
be a desirable means to enhance glucose uptake and lower blood
glucose concentrations, without off-target effects in other tissues.
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Contraction regulates site-speciﬁc phosphorylation of TBC1D1
in skeletal muscle
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Figure S1 Speciﬁcity of anti-phospho-TBC1D1 Ser231, Thr590,S e r 660 and Ser700 antibodies
Point mutations of the TBC1D1 phosphorylation sites Ser231 (S231A), Thr590 (T590A), Ser660 (S660A) and Ser700 (S700A) to alanine were generated separately. Empty vector (EV) control, TBC1D1
WT and the four TBC1D1 single alanine mutants were injected into tibialis anterior muscles followed by in vivo electroporation. Muscles were collected 1 week later. Immunoblotting was with
anti-phospho-TBC1D1 (A)S e r 231,( B)S e r 660,( C)S e r 700 and (D) Thr590 antibodies. Data are means+ −S.E.M.; n = 3–6/group. Au, arbitrary units.
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Figure S2 TBC1D1 Ser231,S e r 660 and Ser700 phosphorylation are not increased by insulin
(A) Maximal insulin injection did not affect TBC1D1 Ser231 phosphorylation in ICR mice. Mice were fasted and injected intraperitoneally with maximal insulin, and tibialis anterior muscles were
dissected10minlater.(B)Akt2 KOhadnormallevelsofbasalandinsulin-stimulated TBC1D1Ser231 phosphorylation.(C)MaximalinsulininjectiondidnotaffectTBC1D1Ser660 phosphorylationin
ICR mice. (D) Akt2 KO had normal levels of basal and insulin-stimulated TBC1D1 Ser660 phosphorylation. (E) Maximal insulin injection did not affect TBC1D1 Ser700 phosphorylation in ICR mice.
(F) Akt2 KO had normal levels of basal and insulin-stimulated TBC1D1 Ser700 phosphorylation. Data are means+ −S.E.M.; n = 5–7/group. Au, arbitrary units.
Figure S3 TBC1D1 Ser590 was not increased by contraction or AICAR
(A) Contractionin situ for 15 mindid notincreaseTBC1D1Ser590 phosphorylationin tibialis anterior musclesfrom ICRmice.(B) AICARincubationdid notincreaseTBC1D1Ser590 phosphorylation
in EDL muscles from ICR mice. Data are means+ −S.E.M.; n = 5–7/group. Au, arbitrary units.
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Figure S4 Single point mutations of TBC1D1 do not alter glucose uptake
Aseparatecohortofmice,includingdifferentcontrolemptyvector(EV)andWTTBC1D1-injected
mice were used to characterize the effects of single mutations on glucose uptake. Individual
point mutations of the TBC1D1 phosphorylation sites Ser231 (S231A), Thr590 (T590A), Ser660
(S660A) and Ser700 (S700A) to alanine were generated. EV control, TBC1D1 WT and the four
TBC1D1 single alanine mutants were injected into tibialis anterior muscles followed by in vivo
electroporationand7dayslaterbasalandcontraction-stimulatedglucoseuptakeweremeasured
in vivo. Basal and contraction-stimulated glucose uptake were not affected by overexpression
of WT TBC1D1 or single mutant TBC1D1. Data are means+ −S.E.M.; n = 4–12/group.
Table S1 Characteristics of high-fat-fed animals
Mice were fed a high-fat diet (60% kcal of fat) for 9 weeks. Mice fed the high-fat diet had
signiﬁcantly higher body weights, fasting blood glucose concentrations and fasting insulin
concentrations compared with chow-fed mice. Data are means+ −S.E.M.; n = 6/group.
*P < 0.05 compared with the chow diet.
Characteristic Chow (n = 6) High fat (n = 6)
Body weight (g) 25.2 + − 1.2 33.4 + − 1.2*
Glucose levels (mg/dl) 142.0 + − 17.4 185.2 + − 8.5*
Insulin levels (ng/ml) 0.68 + − 0.12 2.42 + − 0.16*
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